# Current Status of Newborn Screening in Southeastern and Central Europe

**Authors:** Nika Požun, Daša Perko, Violeta Anastasovska, Ivo Barić, Mihail Baša, Tadej Battelino, Iva Bilandžija, Ian Brincat, Miloš Brkušanin, Maja Djordević, Ivanka Dimova, Ana Drole Torkar, Ksenija Fumić, Sergiu Gladun, Panagiotis Girginoudis, Ildikó Szatmári, Ivana Kavečan, Jasmina Katanić, Vjosa Kotori, Nina Marić, Jelena Martić, Olja Manđarelo, Tatjana Milenković, Matej Mlinarič, Florentina Moldovanu, Michaela Nanu, Péter Monostori, Iskra Modeva, Branka Opančina, Dimitris Platis, Maja Raičević, Žiga Iztok Remec, Barbka Repič Lampret, Alexey Savov, Anastasia Skouma, Aleksandar Sovtić, Iva Stoeva, Alma Toromanović, Domen Trampuž, Natalia Usurelu, Jelena Višekruna, Marios Vogazianos, Maximillian Zeyda, Mojca Žerjav Tanšek, Urh Grošelj

PMC · DOI: 10.3390/ijns12010014 · 2026-03-02

## TL;DR

This paper assesses the current state of newborn screening programs in Southeastern and Central Europe, highlighting progress and ongoing challenges.

## Contribution

The study provides an updated evaluation of newborn screening practices and expansion plans in 16 European countries.

## Key findings

- Most countries universally screen for congenital hypothyroidism, with Kosovo establishing a new program.
- Expanded screening using tandem mass spectrometry is available in nine countries.
- Spinal muscular atrophy screening is now universal in five countries.

## Abstract

Newborn screening (NBS) is a well-established public health program that enables early detection and treatment of rare disorders in newborns, preventing severe complications or death. Despite its recognized importance, the scope and implementation of NBS programs vary across Southeastern (SE) and Central Europe. This study aimed to evaluate the current status of NBS in 16 countries of SE and Central Europe and assess progress since the previous survey in 2021. A structured questionnaire was distributed to national experts between April and December 2025, collecting data on program organization, coverage, diseases included, laboratory methods, confirmatory testing, consent practices, and future expansion plans. All countries reported universal screening for congenital hypothyroidism, except Kosovo, where a national NBS is in the process of being established. Expanded NBS using tandem mass spectrometry was available in Austria, Bulgaria, Croatia, Cyprus, Greece, Hungary, North Macedonia, Romania, and Slovenia. Spinal muscular atrophy screening became universal in Austria, Croatia, Hungary, Serbia, and Slovenia. Most countries reported plans for further expansion, with congenital adrenal hyperplasia, severe combined immunodeficiency, spinal muscular atrophy, and cystic fibrosis being the most frequently targeted conditions. Although notable infrastructural progress has been achieved, financial constraints, lack of staff, and organizational barriers remain key challenges. The study’s assessment of program effectiveness was further limited by the absence of region-wide systems for capturing end-to-end performance indicators, such as the age of the infant at treatment initiation or missed cases. Regional collaboration and adoption of best practices are therefore vital to ensure equitable access and continuous advancement of NBS programs.

## Linked entities

- **Diseases:** congenital hypothyroidism (MONDO:0018612), spinal muscular atrophy (MONDO:0001516), congenital adrenal hyperplasia (MONDO:0015898), severe combined immunodeficiency (MONDO:0015974), cystic fibrosis (MONDO:0009061)

## Full-text entities

- **Genes:** G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}, CBLC (Cbl proto-oncogene C) [NCBI Gene 23624] {aka CBL-3, CBL-SL, RNF57}, MMAA (metabolism of cobalamin associated A) [NCBI Gene 166785] {aka cblA}, CBLB (Cbl proto-oncogene B) [NCBI Gene 868] {aka ADMIO3, Cbl-b, Nbla00127, RNF56}, COPG2IT1 (COPG2 imprinted transcript 1) [NCBI Gene 53844] {aka CIT1, COPG2AS, DKFZP761N09121, NCRNA00170}, PAH (phenylalanine hydroxylase) [NCBI Gene 5053] {aka PH, PKU, PKU1}, CPT2 (carnitine palmitoyltransferase 2) [NCBI Gene 1376] {aka CPT1, CPTASE, IIAE4}
- **Diseases:** CUD (MESH:C536778), Glucose-6-phosphate dehydrogenase deficiency (MESH:D005955), Propionic academia (MESH:D056693), -linked agammaglobulinemia (MESH:C537409), Cbl (MESH:C564747), Long-chain hydroxyacyl-CoA dehydrogenase deficiency (MESH:C566945), CMV (MESH:D003586), Very long-chain acyl-CoA dehydrogenase deficiency (MESH:C536353), Lysosomal storage disorders (MESH:D016464), inborn disorders (MESH:D030342), BTD (MESH:D028921), beta-ketothiolase deficiency (MESH:C535434), CH (MESH:D003409), IVA (MESH:C538167), PA (MESH:C535387), H-PHE (MESH:D000848), GA1 (MESH:C536833), HBPs (MESH:D006453), Hyperphenylalaninemia (MESH:D010661), Carnitine palmitoyltransferase deficiency type 1 (MESH:C535588), Holocarboxylase synthetase deficiency (MESH:D028922), Carnitine palmitoyltransferase deficiency type 2 (MESH:C535589), vitamin B12 deficiency (MESH:D014806), IEM (MESH:D008661), SCID (MESH:D016511), CAH (MESH:D000312), CF (MESH:D003550), Medium-chain acyl-CoA dehydrogenase deficiency (MESH:C536038), GA2 (MESH:D054069), MMA (MESH:C537358), death (MESH:D003643), 2-MBG:2-Methylbutyrylglycinuria (MESH:D020803), 3HMG:3-Hydroxy-3-methylglutaric aciduria (MESH:C538324), NBS (MESH:D006475), Citrullinemia type 1 (MESH:D020159), RMDs (MESH:D009358), Hypoxanthine-guanine phosphoribo-syltransferase deficiency (MESH:D007926), Classic galactosemia (MESH:D005693), metabolic diseases (MESH:D008659), tyrosinemia type I (MESH:D020176), Classical homocystinuria (MESH:D006712), injury to (MESH:D014947), SMA (MESH:D009134), HSD (OMIM:143095), Citrullinemia type 2 (MESH:C536398), MSUD (MESH:D008375), Arginase deficiency (MESH:D020162)
- **Chemicals:** ninhydrin (MESH:D009555), cobalamin (MESH:D014805), thyrotropin (MESH:D013972), steroid (MESH:D013256), lanthanide (MESH:D028581), cobalamin-related (-), Phe (MESH:D010649)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13026941/full.md

---
Source: https://tomesphere.com/paper/PMC13026941